These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 18779469)

  • 1. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
    Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
    Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
    Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
    J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study.
    Tincani E; Mannucci C; Casolari B; Turrini F; Crowther MA; Prisco D; Cenci AM; Bondi M
    Haematologica; 2006 Jul; 91(7):976-9. PubMed ID: 16757417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study.
    Kani C; Markantonis SL; Nicolaou C; Maggina N
    J Crit Care; 2006 Mar; 21(1):79-84. PubMed ID: 16616629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalteparin versus unfractionated heparin in critically ill patients.
    ; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
    N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.
    Perry SL; O'Shea SI; Byrne S; Szczech LA; Ortel TL
    Thromb Haemost; 2006 Dec; 96(6):750-5. PubMed ID: 17139369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.
    Jochberger S; Mayr V; Luckner G; Fries DR; Mayr AJ; Friesenecker BE; Lorenz I; Hasibeder WR; Ulmer H; Schobersberger W; Dünser MW
    Crit Care; 2005 Oct; 9(5):R541-8. PubMed ID: 16277716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J; Johnston N; Siegbahn A
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.
    Cook D; Douketis J; Meade M; Guyatt G; Zytaruk N; Granton J; Skrobik Y; Albert M; Fowler R; Hebert P; Pagliarello G; Friedrich J; Freitag A; Karachi T; Rabbat C; Heels-Ansdell D; Geerts W; Crowther M;
    Crit Care; 2008; 12(2):R32. PubMed ID: 18315876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
    Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG
    J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
    Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
    DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
    Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
    Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
    J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
    Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.
    Agnelli G; Bergqvist D; Cohen AT; Gallus AS; Gent M;
    Br J Surg; 2005 Oct; 92(10):1212-20. PubMed ID: 16175516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
    Wilson SJ; Wilbur K; Burton E; Anderson DR
    Haemostasis; 2001; 31(1):42-8. PubMed ID: 11408748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery.
    Douketis JD; Kinnon K; Crowther MA
    Thromb Haemost; 2002 Jul; 88(1):37-40. PubMed ID: 12152674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation.
    Barbour LA; Oja JL; Schultz LK
    Am J Obstet Gynecol; 2004 Sep; 191(3):1024-9. PubMed ID: 15467584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.